Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Angiotensin (1-7) Mechanisms, Clinical Applications, and Res

    2025-08-06

    Angiotensin (1-7): Mechanisms, Clinical Applications, and Research Perspectives

    Introduction
    Angiotensin (1-7) [Ang-(1-7)] is a heptapeptide hormone derived from the renin-angiotensin system (RAS), a critical regulator of cardiovascular, renal, and metabolic homeostasis. Unlike the classical RAS effector angiotensin II (Ang II), which primarily mediates vasoconstriction, sodium retention, and pro-inflammatory effects, Ang-(1-7) exerts vasodilatory, anti-proliferative, anti-fibrotic, and anti-inflammatory actions. These effects are predominantly mediated through the Mas receptor, a G protein-coupled receptor distinct from the angiotensin II type 1 (AT1) and type 2 (AT2) receptors (Santos et al., 2018, Pharmacol Res).

    Ang-(1-7) is generated from Ang II by the action of angiotensin-converting enzyme 2 (ACE2) or directly from angiotensin I (Ang I) via endopeptidases. The peptide’s unique mechanism of action positions it as a counter-regulatory molecule within the RAS, balancing the deleterious effects of Ang II and offering therapeutic potential in a range of pathologies, including hypertension, heart failure, renal disease, and metabolic syndrome (Santos et al., 2013, Nat Rev Drug Discov).

    [Related: tcep-hcl] Clinical Value and Applications
    The clinical value of Ang-(1-7) lies in its ability to modulate cardiovascular, renal, and metabolic functions through mechanisms that oppose those of Ang II. Preclinical and early clinical studies have demonstrated that Ang-(1-7) can lower blood pressure, reduce cardiac and renal fibrosis, improve endothelial function, and attenuate inflammation (Ferreira et al., 2021, Hypertension).

    1. **Cardiovascular Disease**: Ang-(1-7) has been shown to exert antihypertensive effects, improve endothelial function, and reduce cardiac remodeling post-myocardial infarction. Its vasodilatory and anti-fibrotic properties are particularly relevant for patients with hypertension and heart failure (Santos et al., 2018, Pharmacol Res).

    [Related: NHS-SS-Biotin] 2. **Renal Protection**: In models of chronic kidney disease (CKD), Ang-(1-7) reduces proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis. These renoprotective effects are attributed to the inhibition of pro-fibrotic signaling pathways and the reduction of oxidative stress (Pinheiro et al., 2019, Front Pharmacol).

    3. **Metabolic Syndrome and Diabetes**: Ang-(1-7) improves insulin sensitivity, enhances glucose uptake, and reduces adipose tissue inflammation, suggesting a role in the management of metabolic syndrome and type 2 diabetes (Santos et al., 2013, Nat Rev Drug Discov).

    [Related: vx 765] 4. **Pulmonary and Inflammatory Disorders**: Recent studies have explored Ang-(1-7) as a potential therapeutic agent in acute lung injury and COVID-19, due to its anti-inflammatory and anti-fibrotic actions (Verdecchia et al., 2020, Eur J Intern Med).

    Key Challenges and Pain Points Addressed
    Current treatments for cardiovascular and renal diseases, such as ACE inhibitors, angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists, primarily target the suppression of Ang II activity. However, these therapies do not directly enhance the protective arm of the RAS, represented by Ang-(1-7) and its receptor Mas.

    Key challenges addressed by Ang-(1-7) include:
    - **Incomplete RAS Modulation**: Standard therapies may not fully restore the balance between the deleterious and protective axes of the RAS, especially in advanced disease states (Santos et al., 2018, Pharmacol Res).
    - **Residual Risk**: Despite optimal therapy, patients with hypertension, heart failure, or CKD often exhibit residual risk for adverse outcomes, partly due to insufficient activation of protective pathways.
    - **Fibrosis and Inflammation**: Many current drugs inadequately address tissue fibrosis and chronic inflammation, which are central to the progression of cardiovascular and renal diseases.
    - **Metabolic Dysfunction**: Standard RAS inhibitors have limited efficacy in improving insulin sensitivity or reducing metabolic inflammation.

    By directly activating the Mas receptor, Ang-(1-7) offers a novel approach to address these pain points, providing additive or synergistic benefits when combined with existing therapies.

    Literature Review
    A growing body of literature supports the therapeutic potential of Ang-(1-7) across multiple disease domains:

    1. **Santos et al. (2018, Pharmacol Res)**: This comprehensive review highlights the molecular mechanisms and therapeutic implications of Ang-(1-7), emphasizing its role in cardiovascular and renal protection via Mas receptor activation.

    2. **Ferreira et al. (2021, Hypertension)**: The authors demonstrate that Ang-(1-7) administration in hypertensive animal models leads to significant reductions in blood pressure, cardiac hypertrophy, and fibrosis, supporting its antihypertensive and cardioprotective effects.

    3. **Pinheiro et al. (2019, Front Pharmacol)**: This study investigates the renoprotective effects of Ang-(1-7) in experimental models of CKD, reporting decreased proteinuria, glomerulosclerosis, and oxidative stress markers.

    4. **Verdecchia et al. (2020, Eur J Intern Med)**: The review discusses the potential of Ang-(1-7) in the context of COVID-19, noting its anti-inflammatory and anti-fibrotic actions as relevant to mitigating acute lung injury.

    5. **Santos et al. (2013, Nat Rev Drug Discov)**: This seminal review outlines the discovery, biology, and translational potential of Ang-(1-7), highlighting its beneficial effects in metabolic syndrome and diabetes.

    6. **Gironacci et al. (2020, Clin Sci)**: The authors provide evidence for Ang-(1-7)’s role in improving endothelial function and reducing vascular inflammation, further supporting its utility in cardiovascular disease.

    7. **Klein et al. (2013, Hypertension)**: This clinical study reports that Ang-(1-7) infusion in patients with heart failure is well-tolerated and associated with improved hemodynamic parameters.

    Collectively, these studies underscore the multifaceted therapeutic potential of Ang-(1-7) and provide a strong rationale for its continued investigation.

    Experimental Data and Results
    Preclinical and early clinical studies have elucidated the pharmacological effects of Ang-(1-7) in various disease models:

    - **Cardiovascular Effects**: In spontaneously hypertensive rats, chronic administration of Ang-(1-7) resulted in a significant reduction in systolic blood pressure, attenuation of left ventricular hypertrophy, and decreased myocardial fibrosis (Ferreira et al., 2021, Hypertension). These effects were abrogated by Mas receptor antagonists, confirming receptor specificity.

    - **Renal Protection**: In models of CKD, Ang-(1-7) treatment led to a 40% reduction in proteinuria and a marked decrease in glomerulosclerosis scores compared to controls. Oxidative stress markers, such as malondialdehyde and NADPH oxidase activity, were also significantly reduced (Pinheiro et al., 2019, Front Pharmacol).

    - **Metabolic Benefits**: In high-fat diet-induced obese mice, Ang-(1-7) improved glucose tolerance, enhanced insulin signaling in skeletal muscle, and reduced adipose tissue inflammation (Santos et al., 2013, Nat Rev Drug Discov).

    - **Clinical Data**: In a phase I clinical trial, intravenous infusion of Ang-(1-7) in patients with heart failure was associated with improved cardiac output and reduced systemic vascular resistance, without significant adverse effects (Klein et al., 2013, Hypertension).

    These data collectively support the safety and efficacy of Ang-(1-7) in preclinical and early clinical settings, justifying further investigation in larger, controlled trials.

    Usage Guidelines and Best Practices
    Ang-(1-7) is typically administered via parenteral routes (intravenous, subcutaneous, or intraperitoneal) in preclinical studies, with dosing regimens ranging from 24 to 576 μg/kg/day depending on the disease model and desired pharmacodynamic effect (Ferreira et al., 2021, Hypertension). In clinical studies, intravenous infusion protocols have been employed, with careful monitoring for hemodynamic changes.

    **Key considerations for usage include:**
    - **Route of Administration**: Due to rapid degradation by peptidases, parenteral administration is preferred. Novel formulations, such as cyclodextrin-encapsulated Ang-(1-7), are under investigation to improve oral bioavailability (Santos Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 60 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11472331